Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme

Cançado, Rodolfo Delfini; Lobo, Clarisse; Ângulo, Ivan L.; Araújo, Paulo Ivo Cortez de; Jesus, Joice Aragão de

doi:10.1590/s1516-84842009005000076

Cited by 40 publications

(39 citation statements)

References 21 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Permanence of high MCV, even after the use of HU, was also observed in sickle-cell patients using HU in previous studies (3,17,22) . The HU has also been associated with a decrease in platelet count, total leukocyte reduction and MCH, however, only the first result was observed in our study (5,6,20) . Increased levels of HbF in patients using HU was also observed in other studies (20,21) .…”

Section: Discussioncontrasting

confidence: 66%

Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy

Laurentino¹,

Carvalho²,

Santos

et al. 2014

Jornal Brasileiro De Patologia E Medicina Laboratorial

View full text Add to dashboard Cite

Introduction: Hemoglobin S (HbS) is unstable hemoglobin that easily oxidizes, causing methemoglobin (MetHb) increased production in patients with sickle-cell anemia (SCA). Objectives: To determine MetHb levels and the influence of hydroxyurea (HU) therapy on this marker in patients with SCA. Materials and methods: Blood samples from 53 patients with SCA at the steady-state, with and without HU therapy, and 30 healthy individuals were collected to evaluate MetHb levels. The MetHb measurement was performed by spectrophotometry. Complete blood count, HU measurements, and fetal hemoglobin (HbF) and HbS concentrations were taken from medical records. Results: MetHb levels were statically higher in patients with SCA when compared to control group (p < 0.001). There was no statistical difference in MetHb level between SCA patients, either using or not HU. We obtained a positive correlation between MetHb measurements and HbS concentration (r = 0.2557; p = 0.0323). Conclusion: HbS presence favored hemoglobin breaking down, and consequently increased MetHb production. Treatment with HU, however, did not influence the levels of this marker.

show abstract

Section: Discussioncontrasting

confidence: 66%

Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy

Laurentino¹,

Carvalho²,

Santos

et al. 2014

Jornal Brasileiro De Patologia E Medicina Laboratorial

View full text Add to dashboard Cite

show abstract

“…Response to HU treatment is variable, since the therapeutic response is associated with the clinical severity of the factors modulating SCA, including the concentration of fetal hemoglobin (HbF) in groups with haplotype beta globin, co-association with alpha-thalassemia, and the presence of polymorphisms for XmnI, BCL11A, and HBS1L-MYB (Cokic et al, 2008). Moreover, the variability of the response may be associated with variations in drug metabolism (Cançado et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Standardization method for measurement of hydroxyurea by Ultra High Efficiency Liquid Chromatography in plasma of patients with sickle cell disease

Elias

Carvalho

Soares

et al. 2014

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Sickle cell anemia (SCA) is a recessively inherited disease characterized by chronic hemolytic anemia, chronic inflammation, and acute episodes of hemolysis. Hydroxyurea (HU) is widely used to increase the levels of fetal hemoglobin (HbF). The objective of this study was to standardize and validate a method for the quantification of HU in human plasma by using ultra high performance liquid chromatography (UPLC) in order to determine the plasma HU levels in adult patients with SCA who had been treated with HU. We used an analytical reverse phase column (Nucleosil C18) with a mobile phase consisting of acetonitrile/water (16.7/83.3). The retention times of HU, urea, and methylurea were 6.7, 7.7, and 11.4 min, respectively. All parameters of the validation process were defined. To determine the precision and accuracy of quality controls, HU in plasma was used at concentrations of 100, 740, and 1600 µM, with methylurea as the internal standard. Linearity was assessed in the range of 50-1600 µM HU in plasma, obtaining a correlation coefficient of 0.99. The method was accurate and precise and can be used for the quantitative determination of HU for therapeutic monitoring of patients with SCA treated with HU.

show abstract

“…Sendo assim, vários pesquisadores têm se manifestado a favor do uso deste medicamento, salientando que os riscos relacionados às complicações secundárias à AF são muito mais elevados e graves que os riscos relacionados aos efeitos adversos da HU (CANÇADO et al, 2009). …”

Section: Figura 1 -Diagrama Do Levantamento Bibliográficounclassified

Atividade Farmocológica Hidroxiuréia em Pacientes com Anemia Falciforme

Silva¹,

Rodrigues²,

Sousa³

et al. 2017

RSF

View full text Add to dashboard Cite

Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme

Cited by 40 publications

References 21 publications

Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy

Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy

Standardization method for measurement of hydroxyurea by Ultra High Efficiency Liquid Chromatography in plasma of patients with sickle cell disease

Atividade Farmocológica Hidroxiuréia em Pacientes com Anemia Falciforme

Contact Info

Product

Resources

About